SPECTA Platform for Collecting Cancer Patient Data and Biospecimens to Enhance Research and Clinical Trial Opportunities

What this Trial Is About

Researchers are collecting detailed biological samples, imaging, environmental data, and patient-reported outcomes from cancer patients to support research aimed at understanding tumor biology and improving cancer care. This observational platform supports multiple projects focusing on different tumor types including thorax, head and neck, breast, gastrointestinal, genitourinary, central nervous system, and rare cancers. The goal is to enhance translational research, biomarker discovery, and clinical cancer study access. Participants provide tumor samples and clinical data which are analyzed using various genetic and molecular profiling techniques such as whole exome sequencing, RNA sequencing, and next-generation sequencing panels. Separate projects include studying young adults with rare cancers, molecular characterization of rare tumors, investigating molecular profiles in relation to environmental radon exposure, and assessing circulating tumor DNA as a marker for cancer recurrence. Participants are involved by providing biological material and clinical information, with data collected on tumor biology and treatment effects over five years. The study measures include understanding tumor biology, disease progression, treatment impact, biomarker identification, and matching patients to biomarker-driven clinical trials. Compliance with follow-up and consent are essential, and the study is designed to improve cancer patient care and research over an extended period.

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access